Clinical Trial

Abscopal Effect from the Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy

Study acronym: KROG22-11
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Recently, MD Anderson Cancer Center reported the phase II trial to investigate high-dose radiotherapy (HDRT, 20-70 Gy) and low-dose radiotherapy (LDRT, 1-10 Gy) for metastatic cancer patients who had undergone immunotherapy. HDRT or HDRT+LDRT was conducted in two respective groups and the treatment group was determined according to the disease status of participants, not randomization. Immunotherapy was maintained in this clinical study. Therefore, we aim to investigate this abscopal effect from adding LDRT to HDRT, irrespective of previous immunotherapy, in this multicenter, single-arm study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-16; most recent amendment 2024-12-05.
Trial Details
NCT Number NCT05733156
Lead Sponsor Soonchunhyang University Hospital
Collaborators: SMG-SNU Boramae Medical Center, Saint Vincent's Hospital, Korea, Seoul National University Hospital, Chungnam National University Hospital, Soonchunhyang University Cheonan Hospital
Conditions Neoplasms, Secondary Malignant Neoplasm
Enrollment 52 participants
Start Date 2023-01-03
Primary Completion 2025-12 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2024-12-10